JCSM clinical reports最新文献

英文中文

Is a decrease of grip strength associated with community mobility restriction in dynapenic older women? 老年妇女握力下降是否与社区活动受限有关?

JCSM clinical reports

Pub Date : 2018-01-01 DOI: 10.17987/jcsm-cr.v3i1.42

Margaux Blamoutier, Patrick Boissy, Simon Brière, Geneviève Faucher, Martine Lauzé, Christian Duval

Aims

Absolute grip strength (aGS) measures are not only used to detect dynapenia, but can also provide a robust indicator of functional impairments such as mobility limitations. Mobility limitations can impact community mobility. The main objective of this study was to investigate whether dynapenia status measured with aGS can be used as a predictor of the level of community mobility measured by Global Positioning System (GPS) and the Life-Space Assessment questionnaire (LSA) in healthy older adults. It has been shown that body weight related grip strength (GS/BW) is also a clinical predictor of functional limitation. The secondary objective of the study was to assess the relationship between the community mobility and the GS/BW.

Method and results

The population studied (n=62) was composed of a dynapenic group of women (aged 66.4 ± 4.8) according to an aGS threshold of ≤ 19.9kg and an age-matched group of women (aged 66.1 ± 5.2) with no detectable dynapenia. Clinical and laboratory evaluations were conducted to measure functional capacity tests, body composition and respiratory capacity. Body weigth related to grip strength (GS/BW) was computed. During 12 days, each participant wore a GPS receiver unit with a data logging =−.67) compared system during waking hours. Transit distance in vehicle per day, Transit distance on foot per day and Ellipse area were extracted from the time series of GPS data (longitude, latitude) collected at 1 Hz. The Life space was assessed using a questionnaire. A Wilcoxon test was used to compare the 2 groups for the community mobility measures. Then, data of the 2 groups were pooled to assess the relationship between GS/BW and community mobility measures. A Spearman correlation was used. The dynapenic group had indeed lower aGS (z=−5.3, p≤.05, r=−.67) and GS/BW (z=−5.3, p≤.05, r=−.67)compared to the non-dynapenic group. Furthermore, we found a lower performance to the step test (z=−2.5, p=.011, r=−.32) and lower walking speed (z=−2.1, p=033, r=−.27) for the dynapenic group. However, no significant differences (Wilcoxon signed-ranks test) were found for community mobility measures with the GPS and the LSA between the two groups. There were significant positive relationships between the GS/BW and one leg stand test (r=.353, p=0.005), step test (r=.409, p=0.001) and walking speed (r=.428, p=0.001). No significant relationship (Spearman correlation test) was found for the GS/BW and community mobility measures with the GPS and the LSA.

Conclusions

绝对握力(aGS)测量不仅用于检测运动障碍，而且还可以提供功能障碍(如活动受限)的可靠指标。流动性限制会影响社区流动性。本研究的主要目的是探讨aGS测量的运动障碍状态是否可以作为全球定位系统(GPS)和生活空间评估问卷(LSA)测量的健康老年人社区活动水平的预测因子。研究表明，体重相关握力(GS/BW)也是功能限制的临床预测指标。研究的次要目的是评估社区流动性与GS/BW之间的关系。方法与结果研究人群(n=62)分为aGS阈值≤19.9kg的动态组(66.4±4.8岁)和年龄匹配组(66.1±5.2岁)，未检测到动态。进行了临床和实验室评估，以测量功能测试、身体成分和呼吸能力。计算与握力相关的体重(GS/BW)。在12天的时间里，每个参与者在醒着的时候都戴着一个GPS接收器，该接收器具有数据记录= - 0.67)比较系统。从1 Hz采集的GPS数据(经纬度)时间序列中提取每天车辆过境距离、每天步行过境距离和椭圆面积。生活空间使用问卷进行评估。采用Wilcoxon检验比较两组的社区流动性措施。然后，将两组的数据汇总，评估GS/BW与社区流动措施之间的关系。采用Spearman相关性。动力组aGS确实较低(z= - 5.3, p≤)。05, r= - 0.67)， GS/BW (z= - 5.3, p≤。05, r= - 0.67)。此外，我们发现阶跃检验的性能较低(z= - 2.5, p=。011, r= - 0.32)和较低的步行速度(z= - 2.1, p=033, r= - 0.27)。然而，在GPS和LSA的社区流动性测量中，两组之间没有发现显著差异(Wilcoxon sign -rank检验)。GS/BW与单腿站立试验呈显著正相关(r=。353, p=0.005)，步进检验(r=。409, p=0.001)和步行速度(r= 0.001)。428年,p = 0.001)。GS/BW、社区流动性指标与GPS、LSA均无显著相关(Spearman相关检验)。结论本研究证实aGS和GS/BW是通过临床和实验室评估衡量活动受限的良好指标。然而，握力本身不应被视为老年人动态人群社区活动受限的指标。

{"title":"Is a decrease of grip strength associated with community mobility restriction in dynapenic older women?","authors":"Margaux Blamoutier, Patrick Boissy, Simon Brière, Geneviève Faucher, Martine Lauzé, Christian Duval","doi":"10.17987/jcsm-cr.v3i1.42","DOIUrl":"10.17987/jcsm-cr.v3i1.42","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>Absolute grip strength (aGS) measures are not only used to detect dynapenia, but can also provide a robust indicator of functional impairments such as mobility limitations. Mobility limitations can impact community mobility. The main objective of this study was to investigate whether dynapenia status measured with aGS can be used as a predictor of the level of community mobility measured by Global Positioning System (GPS) and the Life-Space Assessment questionnaire (LSA) in healthy older adults. It has been shown that body weight related grip strength (GS/BW) is also a clinical predictor of functional limitation. The secondary objective of the study was to assess the relationship between the community mobility and the GS/BW.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method and results</h3>\u0000 \u0000 <p>The population studied (n=62) was composed of a dynapenic group of women (aged 66.4 ± 4.8) according to an aGS threshold of ≤ 19.9kg and an age-matched group of women (aged 66.1 ± 5.2) with no detectable dynapenia. Clinical and laboratory evaluations were conducted to measure functional capacity tests, body composition and respiratory capacity. Body weigth related to grip strength (GS/BW) was computed. During 12 days, each participant wore a GPS receiver unit with a data logging =−.67) compared system during waking hours. <i>Transit distance in vehicle per day</i>, <i>Transit distance on foot per day</i> and <i>Ellipse area</i> were extracted from the time series of GPS data (longitude, latitude) collected at 1 Hz. The <i>Life space</i> was assessed using a questionnaire. A Wilcoxon test was used to compare the 2 groups for the community mobility measures. Then, data of the 2 groups were pooled to assess the relationship between GS/BW and community mobility measures. A Spearman correlation was used. The dynapenic group had indeed lower aGS (z=−5.3, p≤.05, r=−.67) and GS/BW (z=−5.3, p≤.05, r=−.67)compared to the non-dynapenic group. Furthermore, we found a lower performance to the step test (z=−2.5, p=.011, r=−.32) and lower walking speed (z=−2.1, p=033, r=−.27) for the dynapenic group. However, no significant differences (Wilcoxon signed-ranks test) were found for community mobility measures with the GPS and the LSA between the two groups. There were significant positive relationships between the GS/BW and <i>one leg stand</i> test (<i>r</i>=.353, <i>p</i>=0.005), <i>step test</i> (<i>r</i>=.409, <i>p</i>=0.001) and <i>walking speed</i> (<i>r</i>=.428, <i>p</i>=0.001). No significant relationship (Spearman correlation test) was found for the GS/BW and community mobility measures with the GPS and the LSA.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 ","PeriodicalId":73543,"journal":{"name":"JCSM clinical reports","volume":"3 1","pages":"1-9"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.17987/jcsm-cr.v3i1.42","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45289546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

SARC-F questionnaire identifies physical limitations and predicts post discharge outcomes in elderly patients with cardiovascular disease SARC-F问卷确定老年心血管疾病患者的身体限制并预测出院后的预后

JCSM clinical reports

Pub Date : 2018-01-01 DOI: 10.17987/jcsm-cr.v3i1.56

Shinya Tanaka, Kentaro Kamiya, Nobuaki Hamazaki, Ryota Matsuzawa, Kohei Nozaki, Yuta Ichinosawa, Manae Harada, Takeshi Nakamura, Emi Maekawa, Chiharu Noda, Minako Yamaoka-Tojo, Atsuhiko Matsunaga, Takashi Masuda, Junya Ako

Background

A simple and inexpensive sarcopenia screening tool would be beneficial in clinical practice. This study was performed to determine whether SARC-F questionnaire can be used to identify physical limitations and poor prognosis in elderly cardiovascular disease (CVD) patients.

Methods and results

The study population consisted of 257 Japanese patients ≥65 years old admitted to our hospital for CVD. Prior to discharge from hospital, SARC-F, handgrip strength, usual gait speed, short physical performance battery score, and 6-minute walking distance were measured in all patients. The patients were divided into two groups according to SARC-F score: SARC-F <4 and SARC-F ≥4. The study endpoint was the first occurrence of all-cause emergency readmission or all-cause mortality. The prevalence rate of SARC-F ≥4 was 26.8%, and increased with age and number of comorbidities. Even after adjusting for covariates, physical function was significantly poorer and the risks of physical function measurements below the critical cut-off values were higher in the SARC-F ≥4 group compared to the SARC-F <4 group. Sixty (23.3%) patients were readmitted and 17 (6.6%) died over a median follow-up period of 11 months (interquartile range: 6–13 months). SARC-F score was a significant predictor of adverse events after discharge. Patients with SARC-F ≥4 showed higher event risk than those with SARC-F <4 (adjusted hazard ratio: 1.78; 95% confidence interval: 1.03–3.07; P = 0.040).

Conclusions

SARC-F questionnaire is useful to identify patients at high risk of physical limitations and to predict post-discharge outcomes in elderly CVD patients.

背景一种简单、廉价的肌少症筛查工具将有助于临床实践。本研究旨在确定SARC-F问卷是否可以用于识别老年心血管疾病(CVD)患者的身体限制和不良预后。方法和结果研究人群包括257例年龄≥65岁的日本CVD患者。出院前，测量所有患者的SARC-F、握力、通常步态速度、短时体能电池评分和6分钟步行距离。根据SARC-F评分将患者分为SARC-F <4和SARC-F≥4两组。研究终点为首次发生的全因紧急再入院或全因死亡。SARC-F≥4的患病率为26.8%，随年龄和合并症数量的增加而增加。即使在调整协变量后，与SARC-F <4组相比，SARC-F≥4组的身体功能明显较差，身体功能测量低于临界临界值的风险更高。60例(23.3%)患者再次入院，17例(6.6%)患者死亡，中位随访时间为11个月(四分位数范围:6-13个月)。SARC-F评分是出院后不良事件的显著预测因子。SARC-F≥4的患者发生事件的风险高于SARC-F≥4的患者(校正风险比:1.78;95%置信区间:1.03-3.07;P = 0.040)。结论SARC-F问卷有助于识别老年CVD患者身体受限的高危患者，并预测其出院后的预后。

{"title":"SARC-F questionnaire identifies physical limitations and predicts post discharge outcomes in elderly patients with cardiovascular disease","authors":"Shinya Tanaka, Kentaro Kamiya, Nobuaki Hamazaki, Ryota Matsuzawa, Kohei Nozaki, Yuta Ichinosawa, Manae Harada, Takeshi Nakamura, Emi Maekawa, Chiharu Noda, Minako Yamaoka-Tojo, Atsuhiko Matsunaga, Takashi Masuda, Junya Ako","doi":"10.17987/jcsm-cr.v3i1.56","DOIUrl":"10.17987/jcsm-cr.v3i1.56","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>A simple and inexpensive sarcopenia screening tool would be beneficial in clinical practice. This study was performed to determine whether SARC-F questionnaire can be used to identify physical limitations and poor prognosis in elderly cardiovascular disease (CVD) patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and results</h3>\u0000 \u0000 <p>The study population consisted of 257 Japanese patients ≥65 years old admitted to our hospital for CVD. Prior to discharge from hospital, SARC-F, handgrip strength, usual gait speed, short physical performance battery score, and 6-minute walking distance were measured in all patients. The patients were divided into two groups according to SARC-F score: SARC-F <4 and SARC-F ≥4. The study endpoint was the first occurrence of all-cause emergency readmission or all-cause mortality. The prevalence rate of SARC-F ≥4 was 26.8%, and increased with age and number of comorbidities. Even after adjusting for covariates, physical function was significantly poorer and the risks of physical function measurements below the critical cut-off values were higher in the SARC-F ≥4 group compared to the SARC-F <4 group. Sixty (23.3%) patients were readmitted and 17 (6.6%) died over a median follow-up period of 11 months (interquartile range: 6–13 months). SARC-F score was a significant predictor of adverse events after discharge. Patients with SARC-F ≥4 showed higher event risk than those with SARC-F <4 (adjusted hazard ratio: 1.78; 95% confidence interval: 1.03–3.07; P = 0.040).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>SARC-F questionnaire is useful to identify patients at high risk of physical limitations and to predict post-discharge outcomes in elderly CVD patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":73543,"journal":{"name":"JCSM clinical reports","volume":"3 1","pages":"1-11"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.17987/jcsm-cr.v3i1.56","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46759575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

JCSM clinical reports

Pub Date : 2018-01-01 DOI: 10.17987/jcsm-cr.v3i1.46

Rogier L. C. Plas, Klaske van Norren, Harm van Baar, Carla van Aller, Maarten de Bakker, Nadia Botros, Renger F. Witkamp, Annebeth Haringhuizen, Ellen Kampman, Renate Winkels

Chemotherapeutic treatment is regularly accompanied by side‐effects. Hydrophilic chemotherapeutics such as capecitabine and oxaliplatin (CAPOX), often used in colorectal cancer treatment, predominantly accumulate in non‐adipose tissues. Therefore the aim of this paper was to investigate whether body composition and fat infiltration in the muscle (muscle attenuation and intermuscular‐adipose‐tissue [IMAT] content) are associated with chemotherapy‐induced toxicities.

目的化疗通常伴随着副作用。常用于结直肠癌治疗的卡培他滨和奥沙利铂(CAPOX)等亲水化疗药物主要积聚在非脂肪组织中。因此，本文的目的是研究身体成分和肌肉中的脂肪浸润(肌肉衰减和肌间脂肪组织[IMAT]含量)是否与化疗引起的毒性有关。方法在这项回顾性观察性研究中，我们收集了2006年至2015年期间接受CAPOX辅助化疗的115例结直肠癌患者的数据。有关癌症特征的信息来自荷兰癌症登记处。检索诊断性CT扫描以评估第三腰椎骨骼肌和脂肪组织的横截面积。从医学图表中检索剂量限制性毒性[DLT]和相对给药剂量(占基于bsa的计划剂量的百分比)的信息。使用cox回归和线性回归分析确定身体成分、肌肉质量和化疗引起的毒性之间的关系。结果:我们发现在我们的队列中，DLT的发生率为90%:50%的患者减少了剂量，30%的患者推迟了下一个周期，4%的患者完全停止治疗，6%的患者在第一次DLT时住院。最常见的是减少奥沙利铂的剂量，同时保持卡培他滨的剂量不变。Cox回归分析显示，在第一个治疗周期或到第一次DLT的时间内，身体成分或肌肉质量与DLT没有关联。多元线性回归显示，较高的IMAT指数和IMAT肌肉百分比与较低的奥沙利铂相对给药剂量相关。结论结论;在这些接受CAPOX治疗的CRC患者中，只有IMAT与剂量限制性毒性相关，而骨骼或脂肪区域与剂量限制性毒性无关。

引用次数: 2

Sarcopenia is a Significant Predictor of Mortality After Abdominal Aortic Aneurysm Repair 肌少症是腹主动脉瘤修复后死亡率的重要预测因子

JCSM clinical reports

Pub Date : 2018-01-01 DOI: 10.17987/jcsm-cr.v3i1.53

Joshua K. Kays MD, Tiffany W. Liang MD, Teresa A. Zimmers PhD, Daniel P. Milgrom MD, Hamzah Abduljabar BS, Andrew Young BS, Bradford J. Kim MD MHS, Teresa M. Bell PhD, Andres Fajardo MD, Michael P. Murphy MD, Leonidas G. Koniaris MD MBA

Aims

Repair of abdominal aortic aneurysms (AAA) decreases the incidence of rupture and death. In cancer patients, sarcopenia has been associated with increased surgical complications and mortality. The impact of sarcopenia on survival after AAA repair has yet to be described.

Methods and Results

Patient demographic, laboratory, body composition measurements and survival data were obtained from patients undergoing AAA repair at the Indiana University medical campus over a 5-year period. Univariate and multivariate analyses were performed to identify factors associated with overall survival. Overall, 58.2% presented with sarcopenia. Sarcopenic patients were older (71.8±8.3 versus 66.8±8.1 years; p<0.001), had lower body mass index (BMI) (26.3±5.2 versus 31.5±5.9 kg/m²; p<0.001), higher rates of myosteatosis (84.4% versus 52.%; p<0.001), greater AAA diameter (60.6±14.0 versus 57.8±11.7 mm; p=0.016), higher Charlson Comorbidity Index (CCI) (32.3% versus 25.1% ≥6; p=0.034), and increased rates of rupture (8.2% versus 3.8%; p=0.047). Sarcopenic and nonsarcopenic patients had no difference in 30-day morbidity (8.5% versus 8.5%; p=0.991) or mortality (3.7% versus 0.9%; p=0.07). Univariate analysis demonstrated age, sarcopenia, myosteatosis, CCI, and BMI to be associated with long-term survival. There was no correlation between BMI and sarcopenia. Both sarcopenia and myosteatosis resulted in decreased one-, three-, and five-year survivals compared to their counterparts. On multivariate analysis sarcopenia is independently associated with survival, conferring a 1.6-fold increase in death (p=0.04). The combination of sarcopenia plus myosteatosis doubled the risk of death compared to sarcopenia alone.

Conclusions

This is the first study to demonstrate that over half of all patients undergoing AAA repair are sarcopenic, a condition associated with increased mortality. Sarcopenia with myosteatosis is associated with double the mortality of sarcopenia alone. CT scan, but not BMI, accurately identifies sarcopenia and myosteatosis. Defining the mechanisms through which sarcopenia contributes to late death after AAA repair is critical to developing novel interventions that may improve survival in this high risk population.

目的腹主动脉瘤修复术可降低其破裂和死亡的发生率。在癌症患者中，肌肉减少症与手术并发症和死亡率增加有关。肌少症对AAA修复后存活的影响尚未被描述。方法和结果在印第安纳大学医学院接受AAA修复的患者中获得了5年的患者人口统计学、实验室、身体成分测量和生存数据。进行单因素和多因素分析以确定与总生存率相关的因素。总体而言，58.2%表现为肌肉减少症。肌肉减少症患者年龄较大(71.8±8.3岁vs 66.8±8.1岁);p<0.001)，体重指数(BMI)较低(26.3±5.2 vs 31.5±5.9 kg/m2;P<0.001)，骨骼肌病的发病率更高(84.4%对52.2%;p<0.001)，更大的AAA直径(60.6±14.0 vs 57.8±11.7 mm;p=0.016)，较高的Charlson合并症指数(CCI) (32.3% vs 25.1%≥6;P =0.034)，破裂率增加(8.2% vs 3.8%;p = 0.047)。肌肉减少症和非肌肉减少症患者的30天发病率无差异(8.5% vs 8.5%;P =0.991)或死亡率(3.7% vs 0.9%;p = 0.07)。单因素分析表明，年龄、肌肉减少症、肌骨化症、CCI和BMI与长期生存相关。BMI和肌肉减少症之间没有相关性。与同类患者相比，肌肉减少症和骨骼肌病的1年、3年和5年生存率均下降。在多变量分析中，肌肉减少症与生存率独立相关，死亡率增加1.6倍(p=0.04)。与单纯的肌肉减少症相比，肌肉减少症合并肌骨化症的死亡风险增加了一倍。这是首次有研究表明，接受AAA修复的患者中有一半以上是肌肉减少症，这种疾病与死亡率增加有关。肌少症合并骨骼肌病的死亡率是单纯肌少症的两倍。CT扫描，而不是BMI，可以准确地识别肌肉减少症和肌骨化症。明确肌少症导致AAA修复后晚期死亡的机制，对于开发新的干预措施，提高这一高危人群的生存率至关重要。

{"title":"Sarcopenia is a Significant Predictor of Mortality After Abdominal Aortic Aneurysm Repair","authors":"Joshua K. Kays MD, Tiffany W. Liang MD, Teresa A. Zimmers PhD, Daniel P. Milgrom MD, Hamzah Abduljabar BS, Andrew Young BS, Bradford J. Kim MD MHS, Teresa M. Bell PhD, Andres Fajardo MD, Michael P. Murphy MD, Leonidas G. Koniaris MD MBA","doi":"10.17987/jcsm-cr.v3i1.53","DOIUrl":"10.17987/jcsm-cr.v3i1.53","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>Repair of abdominal aortic aneurysms (AAA) decreases the incidence of rupture and death. In cancer patients, sarcopenia has been associated with increased surgical complications and mortality. The impact of sarcopenia on survival after AAA repair has yet to be described.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>Patient demographic, laboratory, body composition measurements and survival data were obtained from patients undergoing AAA repair at the Indiana University medical campus over a 5-year period. Univariate and multivariate analyses were performed to identify factors associated with overall survival. Overall, 58.2% presented with sarcopenia. Sarcopenic patients were older (71.8±8.3 versus 66.8±8.1 years; p<0.001), had lower body mass index (BMI) (26.3±5.2 versus 31.5±5.9 kg/m<sup>2</sup>; p<0.001), higher rates of myosteatosis (84.4% versus 52.%; p<0.001), greater AAA diameter (60.6±14.0 versus 57.8±11.7 mm; p=0.016), higher Charlson Comorbidity Index (CCI) (32.3% versus 25.1% ≥6; p=0.034), and increased rates of rupture (8.2% versus 3.8%; p=0.047). Sarcopenic and nonsarcopenic patients had no difference in 30-day morbidity (8.5% versus 8.5%; p=0.991) or mortality (3.7% versus 0.9%; p=0.07). Univariate analysis demonstrated age, sarcopenia, myosteatosis, CCI, and BMI to be associated with long-term survival. There was no correlation between BMI and sarcopenia. Both sarcopenia and myosteatosis resulted in decreased one-, three-, and five-year survivals compared to their counterparts. On multivariate analysis sarcopenia is independently associated with survival, conferring a 1.6-fold increase in death (p=0.04). The combination of sarcopenia plus myosteatosis doubled the risk of death compared to sarcopenia alone.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This is the first study to demonstrate that over half of all patients undergoing AAA repair are sarcopenic, a condition associated with increased mortality. Sarcopenia with myosteatosis is associated with double the mortality of sarcopenia alone. CT scan, but not BMI, accurately identifies sarcopenia and myosteatosis. Defining the mechanisms through which sarcopenia contributes to late death after AAA repair is critical to developing novel interventions that may improve survival in this high risk population.</p>\u0000 </section>\u0000 </div>","PeriodicalId":73543,"journal":{"name":"JCSM clinical reports","volume":"3 1","pages":"1-12"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.17987/jcsm-cr.v3i1.53","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48815673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 18

The experience of weight loss and its associated burden in patients with non‐small cell lung cancer: results of an online survey 非小细胞肺癌患者体重减轻的经历及其相关负担:一项在线调查的结果

JCSM clinical reports

Pub Date : 2017-07-01 DOI: 10.17987/jcsm-cr.v2i2.18

Ana Maria Rodriguez, J. Braverman, Dimple Aggarwal, J. Friend, E. Duus

The main objectives of this study were to characterize and compare the burden of non‐small cell lung cancer (NSCLC) patients reporting considerable unintentional weight loss (≥ 5% in the past 6 months or ≥ 2% for a BMI < 20 kg/m2) to those who did not.

本研究的主要目的是表征和比较非小细胞肺癌(NSCLC)患者的负担，这些患者报告了相当大的意外体重减轻(过去6个月体重减轻≥5%，BMI < 20 kg/m2体重减轻≥2%)与未报告的患者的负担。

引用次数: 8

Prevalence of sarcopenia in community‐dwelling older people of Mexico City using the EGWSOP (European Working Group on Sarcopenia in Older People) diagnostic criteria 使用EGWSOP(欧洲老年人肌肉减少症工作组)诊断标准的墨西哥城社区居住老年人肌肉减少症患病率

JCSM clinical reports

Pub Date : 2017-07-01 DOI: 10.17987/jcsm-cr.v2i2.9

M. C. Espinel-Bermúdez, E. Ramírez-García, C. García-Peña, A. Salvá, L. Ruiz‐Arregui, Ángel Cárdenas-Bahena, S. Sánchez-García

The aim of this study is to determine the prevalence of sarcopenia in community‐dwelling older people living in Mexico City using the EGWSOP (European Working Group on Sarcopenia in Older People) diagnostic criteria that include muscle mass, muscle strength and physical performance.

本研究的目的是使用EGWSOP（欧洲老年人肌肉减少症工作组）诊断标准，包括肌肉质量、肌肉力量和身体表现，来确定墨西哥城社区老年人的肌肉减少症患病率。

引用次数: 12

On the wide field of clinical cachexia, sarcopenia and muscle research 对临床恶病质、肌少症和肌肉的广泛研究

JCSM clinical reports

Pub Date : 2017-07-01 DOI: 10.17987/jcsm-cr.v2i2.36

T. Trippel, N. Ebner, G. Loncar, S. Haehling

The past months have brought an interesting array of international submissions ranging from prognostic implications of body mass index and tissue loss in cancer to chronic kidney disease to this journal. Manuscripts on imaging or biomarkers aspects, among others, draw a heterogeneous picture of clinical reports in the field. Yet, upon completion of JCSM Clinical Reports’ Issue 1, Volume 2 we are delighted to display the rapid progress this editorial project takes on the large topic of cachexia, sarcopenia and muscle research. Coherently, we follow our stringent editorial path and hope to consider and integrate a ‘broad field’ from a clinical point of view.

在过去的几个月里，本杂志收到了一系列有趣的国际投稿，从身体质量指数和癌症组织损失的预后影响到慢性肾脏疾病。关于成像或生物标志物方面的手稿，除其他外，描绘了该领域临床报告的异质图景。然而，在完成《JCSM临床报告》第1期第2卷后，我们很高兴地展示了这个编辑项目在恶病质、肌肉减少症和肌肉研究方面的快速进展。我们始终遵循严格的编辑路径，希望从临床角度考虑和整合一个“广阔的领域”。

引用次数: 0

Mitochondrial respiratory chain deficiency in older men and its relationship with muscle mass and performance 老年男性线粒体呼吸链缺陷及其与肌肉质量和表现的关系

JCSM clinical reports

Pub Date : 2017-07-01 DOI: 10.17987/jcsm-cr.v2i2.35

K. Rygiel, R. Dodds, H. Patel, H. Syddall, L. Westbury, A. Granic, C. Cooper, Joshua Cliff, M. Rocha, D. Turnbull, A. Sayer

Sarcopenia is the loss of muscle mass and physical performance with age, and recognition of its importance in clinical practice is growing. Age‐related decline in muscle mitochondrial function has been described although less is known about the role of mitochondrial dysfunction in sarcopenia. The aim of this study was to investigate whether respiratory chain deficiency is associated with muscle mass and physical performance among a sample of healthy older men participating in the Hertfordshire Sarcopenia Study.

肌肉萎缩症是指肌肉质量和身体机能随着年龄的增长而丧失，人们越来越认识到它在临床实践中的重要性。尽管对线粒体功能障碍在少肌症中的作用知之甚少，但与年龄相关的肌肉线粒体功能下降已被描述。本研究的目的是调查参与赫特福德郡Sarcopenia研究的健康老年男性样本中呼吸链缺乏是否与肌肉质量和身体表现有关。

引用次数: 3

Mediterranean Diet attenuates risk of frailty and sarcopenia: New insights and future directions 地中海饮食降低虚弱和肌肉减少症的风险:新的见解和未来的方向

JCSM clinical reports

Pub Date : 2017-07-01 DOI: 10.17987/jcsm-cr.v2i2.45

Rebecca McClure, Anthony Villani

Sarcopenia and physical frailty are associated with progressive disability and predictive of negative health outcomes. Dietary interventions are considered the cornerstone in the management of sarcopenic symptomology and physical frailty. However few studies have investigated preventative strategies. Moreover, most studies have focused on the efficacy of individual nutrients or supplements rather than dietary patterns. The Mediterranean Diet (MedDiet) is a dietary pattern that provides evidence for an association between diet quality, healthy ageing and disease prevention. The purpose of this paper was to examine, synthesise and develop a narrative review of the current literature, investigating the potential benefits associated with adherence to a MedDiet and attenuation of physical frailty and sarcopenic symptomology in older adults. We also explored the underlying mechanisms underpinning the potential benefits of the MedDiet on ameliorating physical frailty and sarcopenic symptomology. Synthesis of the reviewed literature is suggestive of a decreased risk of physical frailty and sarcopenic symptomology with greater adherence to a MedDiet. We identified the anti-inflammatory and high antioxidant components of the MedDiet as two potential biological mechanisms involved. Due to a lack of evidence from RCTs to support the proposed physiological mechanisms, we suggest investigating these observations in older adults with type 2 diabetes (T2DM) whom are vulnerable to physical frailty and disability. A number of biological mechanisms describing the pathway to disability in older adults with T2DM have been postulated with many of these mechanisms potentially mitigated with dietary interventions involving the MedDiet. Exploring these mechanisms with the use of well-designed, longer-term dietary intervention studies in older adults with an increased vulnerability to physical frailty and sarcopenia is warranted.

肌肉减少症和身体虚弱与进行性残疾有关，并预示着负面的健康结果。饮食干预被认为是管理肌肉减少症状和身体虚弱的基石。然而，很少有研究调查了预防策略。此外，大多数研究都集中在个别营养素或补充剂的功效上，而不是饮食模式。地中海饮食(MedDiet)是一种饮食模式，为饮食质量、健康老龄化和疾病预防之间的联系提供了证据。本文的目的是检查、综合和发展当前文献的叙述性回顾，调查坚持MedDiet和减轻老年人身体虚弱和肌肉减少症状相关的潜在益处。我们还探讨了MedDiet在改善身体虚弱和肌肉减少症状方面的潜在益处的潜在机制。综合所回顾的文献表明，更坚持MedDiet可以降低身体虚弱和肌肉减少症状的风险。我们确定了MedDiet的抗炎和高抗氧化成分是两种潜在的生物学机制。由于缺乏随机对照试验的证据来支持所提出的生理机制，我们建议在易患身体虚弱和残疾的老年2型糖尿病(T2DM)患者中研究这些观察结果。许多描述老年2型糖尿病致残途径的生物学机制已经被假设，其中许多机制可能通过包括MedDiet在内的饮食干预得到缓解。通过精心设计的长期饮食干预研究，探索这些机制，对身体虚弱和肌肉减少症的老年人进行研究是有必要的。

{"title":"Mediterranean Diet attenuates risk of frailty and sarcopenia: New insights and future directions","authors":"Rebecca McClure, Anthony Villani","doi":"10.17987/jcsm-cr.v2i2.45","DOIUrl":"10.17987/jcsm-cr.v2i2.45","url":null,"abstract":"<div>\u0000 \u0000 <p>Sarcopenia and physical frailty are associated with progressive disability and predictive of negative health outcomes. Dietary interventions are considered the cornerstone in the management of sarcopenic symptomology and physical frailty. However few studies have investigated preventative strategies. Moreover, most studies have focused on the efficacy of individual nutrients or supplements rather than dietary patterns. The Mediterranean Diet (MedDiet) is a dietary pattern that provides evidence for an association between diet quality, healthy ageing and disease prevention. The purpose of this paper was to examine, synthesise and develop a narrative review of the current literature, investigating the potential benefits associated with adherence to a MedDiet and attenuation of physical frailty and sarcopenic symptomology in older adults. We also explored the underlying mechanisms underpinning the potential benefits of the MedDiet on ameliorating physical frailty and sarcopenic symptomology. Synthesis of the reviewed literature is suggestive of a decreased risk of physical frailty and sarcopenic symptomology with greater adherence to a MedDiet. We identified the anti-inflammatory and high antioxidant components of the MedDiet as two potential biological mechanisms involved. Due to a lack of evidence from RCTs to support the proposed physiological mechanisms, we suggest investigating these observations in older adults with type 2 diabetes (T2DM) whom are vulnerable to physical frailty and disability. A number of biological mechanisms describing the pathway to disability in older adults with T2DM have been postulated with many of these mechanisms potentially mitigated with dietary interventions involving the MedDiet. Exploring these mechanisms with the use of well-designed, longer-term dietary intervention studies in older adults with an increased vulnerability to physical frailty and sarcopenia is warranted.</p>\u0000 </div>","PeriodicalId":73543,"journal":{"name":"JCSM clinical reports","volume":"2 2","pages":"1-17"},"PeriodicalIF":0.0,"publicationDate":"2017-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.17987/jcsm-cr.v2i2.45","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46713249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 21

Sarcopenia: Prevalence and Prognostic Implications in Elderly Patients with Cardiovascular Disease 骨骼肌减少症:老年心血管疾病患者的患病率和预后意义

JCSM clinical reports

Pub Date : 2017-07-01 DOI: 10.17987/jcsm-cr.v2i2.41

Kentaro Kamiya, Nobuaki Hamazaki, Ryota Matsuzawa, Kohei Nozaki, Shinya Tanaka, Yuta Ichinosawa, Emi Maekawa, Chiharu Noda, Minako Yamaoka-Tojo, Atsuhiko Matsunaga, Takashi Masuda, Junya Ako

Aims

Sarcopenia has recently been given an ICD-10 code. However, there have been no systematic investigations regarding the prevalence or prognostic value of sarcopenia in cardiovascular disease (CVD) according to the international consensus definition. The present study was performed to investigate the prevalence and prognostic value of sarcopenia in elderly patients with CVD.

Methods and results

The study population consisted of 1603 admitted patients aged ≥ 65 years (74.4 ± 6.2 years, 1049 men) with CVD. Sarcopenia was defined according to the recommended diagnostic algorithm of the Asia Working Group for Sarcopenia. The endpoint for the study was all-cause mortality. The overall sarcopenia prevalence rate was 29.7% (19.6% in men and 48.7% in women). The prevalence rates of sarcopenia across major diagnostic categories were as follows: acute coronary syndrome, 17.8%; post-cardiac surgery, 31.8%; and heart failure, 35.2%. During the 2.3 ± 2.1-year follow-up period, 175 deaths occurred. Patients with sarcopenia showed higher risk of all-cause mortality compared with non-sarcopenic patients (adjusted hazard ratio: 1.44; 95% confidence interval: 1.01 – 2.05; P = 0.044).

Conclusions

Sarcopenia is highly prevalent among elderly patients with CVD and is associated with increased mortality risk.

目的肌少症最近被赋予了ICD-10代码。然而，根据国际共识的定义，目前还没有关于心血管疾病(CVD)中肌肉减少症的患病率或预后价值的系统调查。本研究旨在探讨老年心血管疾病患者肌肉减少症的患病率及预后价值。方法和结果研究人群包括1603例年龄≥65岁(74.4±6.2岁，男性1049例)的心血管疾病住院患者。肌少症根据亚洲肌少症工作组推荐的诊断算法进行定义。该研究的终点是全因死亡率。总体肌肉减少症患病率为29.7%(男性19.6%，女性48.7%)。骨骼肌减少症在主要诊断类别的患病率如下:急性冠脉综合征，17.8%;心脏手术后，31.8%;心力衰竭占35.2%。在2.3±2.1年的随访期间，发生175例死亡。与非肌肉减少症患者相比，肌肉减少症患者的全因死亡率更高(校正风险比:1.44;95%置信区间:1.01 - 2.05;P = 0.044)。结论老年CVD患者中肌肉减少症非常普遍，并与死亡风险增加相关。

{"title":"Sarcopenia: Prevalence and Prognostic Implications in Elderly Patients with Cardiovascular Disease","authors":"Kentaro Kamiya, Nobuaki Hamazaki, Ryota Matsuzawa, Kohei Nozaki, Shinya Tanaka, Yuta Ichinosawa, Emi Maekawa, Chiharu Noda, Minako Yamaoka-Tojo, Atsuhiko Matsunaga, Takashi Masuda, Junya Ako","doi":"10.17987/jcsm-cr.v2i2.41","DOIUrl":"10.17987/jcsm-cr.v2i2.41","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>Sarcopenia has recently been given an ICD-10 code. However, there have been no systematic investigations regarding the prevalence or prognostic value of sarcopenia in cardiovascular disease (CVD) according to the international consensus definition. The present study was performed to investigate the prevalence and prognostic value of sarcopenia in elderly patients with CVD.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and results</h3>\u0000 \u0000 <p>The study population consisted of 1603 admitted patients aged ≥ 65 years (74.4 ± 6.2 years, 1049 men) with CVD. Sarcopenia was defined according to the recommended diagnostic algorithm of the Asia Working Group for Sarcopenia. The endpoint for the study was all-cause mortality. The overall sarcopenia prevalence rate was 29.7% (19.6% in men and 48.7% in women). The prevalence rates of sarcopenia across major diagnostic categories were as follows: acute coronary syndrome, 17.8%; post-cardiac surgery, 31.8%; and heart failure, 35.2%. During the 2.3 ± 2.1-year follow-up period, 175 deaths occurred. Patients with sarcopenia showed higher risk of all-cause mortality compared with non-sarcopenic patients (adjusted hazard ratio: 1.44; 95% confidence interval: 1.01 – 2.05; <i>P</i> = 0.044).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Sarcopenia is highly prevalent among elderly patients with CVD and is associated with increased mortality risk.</p>\u0000 </section>\u0000 </div>","PeriodicalId":73543,"journal":{"name":"JCSM clinical reports","volume":"2 2","pages":"1-13"},"PeriodicalIF":0.0,"publicationDate":"2017-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.17987/jcsm-cr.v2i2.41","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41783279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 31

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

JCSM clinical reports

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀

微信

客服QQ

扫码关注我们

反馈

Book学术文献互助群
群号：481959085

文献互助智能选刊最新文献互助须知联系我们：info@booksci.cn

Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。